Clinical Trial Update: Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase II trial evaluating atrasentan in combination with DOXIL for recurrent ovarian, fallopian tube, and peritoneal cancer was terminated; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Atrasentan (atrasentan)
• Doxil (liposomal doxorubicin)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2011-04-21